– Alphyn Biologics presents pediatric data from an atopic dermatitis trial at the European Society for Pediatric Dermatology Congress
ANNAPOLIS, Md., April 27, 2023 /PRNewswire/ — Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapies, will present for the first time new pediatric data from its Phase 2a clinical trial of a topical candidate for mild to moderate atopic dermatitis (AD) at the 22nd Congress of the European Society of Pediatric Dermatology (ESPD), to be held May 4-6 in Malaga, Spain. AB-101a is being developed to uniquely treat the immune and bacterial components of AD in patients 2 years to adult. This pediatric population met all primary endpoints of the clinical trial.
“Atopic dermatitis usually appears in childhood and can become a chronic, lifelong disease,” said Neal Koller, CEO of Alphyn and sponsor of the research featured in the ESPD poster (P198). “We are hopeful that AB-101a will offer children and their physicians the first AD therapy that addresses the immune system component and bacterial complications of AD, including those commonly associated with staphylococcus (Staphylococcus aureus ) and methicillin-resistant staphylococcus, and have a safety profile that supports continued long-term use.”
In January, Alphyn Biologics reported positive results from the first cohort of its Phase 2a clinical trial with AB-101a, a steroid-free topical AD treatment. The trial met all of its primary endpoints, highlighting its potential as a safe and effective AD treatment that may be effective for long-term continued use. The randomized, double-blind, vehicle-controlled trial is evaluating the AB-101a treatment protocol at multiple centers using standard scales for assessing AD.
ABOUT ALPHYN BIOLOGICS
Alphyn Biologics is a clinical-stage dermatology company developing world-class, multi-targeted therapies for serious and prevalent skin conditions based on its AB-101 platform. Its lead product candidate, AB-101a, is being developed as a topical treatment for atopic dermatitis (AD), the most common form of eczema. AB-101a has demonstrated a strong safety profile and is being developed to uniquely target the immune system and bacterial components of AD, making it ideal for treating AD and AD with secondary infection. Alphyn’s AB-101 platform has multiple bioactive compounds and therefore multiple mechanisms of action to support a robust pipeline of dermatology therapeutics that have potential safety, efficacy, and regulatory marketing clearance advantages. Alphyn is headquartered in Annapolis, Maryland, and Cincinnati, Ohio, with a wholly-owned Australian subsidiary. The company went live in 2020 and has raised approximately $6.9 million.
Logo – https://mma.prnewswire.com/media/1899346…
View original content: https://www.prnewswire.com/news-releases/alphyn-biologics-presenta-datos-pediatricos-de-un-ensayo-sobre-dermatitis-atopica-301810030.html
